Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20895847 | 0.94 | DPP4 (0.62) | DPP4CHRM1 | |
| SCHEMBL20895848 | 0.94 | DPP4 (0.62) | DPP4CHRM1 | |
| SCHEMBL1772989 | 0.92 | DPP4 (0.77) | DPP4CHRM1 | |
| SCHEMBL1772988 | 0.92 | DPP4 (0.77) | DPP4CHRM1 | |
| SCHEMBL13946035 | 0.88 | DPP4 (0.51) | DPP4CHRM1 | |
| SCHEMBL8269947 | 0.87 | DPP4 (0.52) | DPP4CHRM1 | |
| SCHEMBL10067751 | 0.84 | DPP4 (0.64) | DPP4CHRM1 | |
| SCHEMBL2609251 | 0.84 | DPP4 (0.68) | DPP4CHRM1 | |
| SCHEMBL12290555 | 0.84 | DPP4 (0.68) | DPP4CHRM1 | |
| SCHEMBL685384 | 0.83 | DPP4 (0.84) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112069-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112069-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | PNP, PURB, NUDT14 | DPP4 3263/4885CHRM1 4301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.